Liquid Biopsy Market - Global Liquid Biopsy Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 – (By Biomarker, By Source, By Clinical Application,By Indication, By Geographic Coverage and By Company)

The global Liquid Biopsy Market is entering a transformative period as demand surges for minimally invasive diagnostic solutions that enable early cancer detection, treatment monitoring, and personalized therapy decisions. The industry is projected to rise from USD 9.1 billion in 2025 to USD 18.05 billion by 2032, registering a CAGR of 10.28% during the forecast period. Growing adoption of precision medicine, increased oncology screening programs, and advancements in biomarker discovery are strengthening the role of liquid biopsy as a critical component of next-generation clinical diagnostics.

Market Insights

Liquid biopsy has evolved from a complementary diagnostic tool to a mainstream clinical technology used across oncology and non-oncology settings. With the ability to analyze circulating biomarkers such as circulating tumour DNA, circulating tumour cells, exomes, and cfRNA, the technology supports real-time assessment of disease progression, recurrence risk, and treatment response. Rising preference for non-invasive testing over traditional tissue biopsies is driving widespread clinical adoption. Increasing investment in multi-cancer early detection (MCED) platforms, rapid commercialization of advanced sequencing technologies, and regulatory support for innovative diagnostics continue to enhance market penetration.

The growing clinical utility of liquid biopsy in early cancer screening, recurrence prediction, and minimal residual disease (MRD) analysis is reshaping diagnostic algorithms. Extensive R&D activity from biotechnology companies and academic institutions is accelerating the development of high-sensitivity assays capable of detecting ultra-low-frequency mutations. Additionally, expansion of decentralized testing and integration of AI-based genomic analysis are broadening the scope for personalized and preventive healthcare.

Drivers

Several key factors are driving revenue growth across the Liquid Biopsy Market:
• Increasing global cancer burden propels demand for early detection and non-invasive diagnostic alternatives.
• Advancements in next-generation sequencing, digital PCR, and multimodal biomarker analysis enhance diagnostic accuracy.
• Growing adoption of personalized treatment plans strengthens the need for real-time monitoring of therapeutic response.
• Rising government and private-sector investments in cancer research and screening programs support broad clinical uptake.
• Technological improvements enabling detection of MRD and rare mutations are expanding the application of liquid biopsy across oncology specialties.
• Shift toward decentralized and home-based sample collection boosts accessibility and patient compliance.

Business Opportunity

The market presents significant opportunities for innovation across biomarker development, AI-enabled genomic analytics, and cost-efficient test manufacturing. Companies are increasingly focusing on multi-cancer early detection tests that can screen for multiple tumour types from a single sample. Partnerships between diagnostic developers, pharmaceutical companies, and clinical research organizations are enabling the integration of liquid biopsy in clinical trials, drug development, and precision oncology workflows. Emerging applications in non-oncology fields such as transplantation monitoring, infectious diseases, and prenatal testing further offer value-creation avenues for market participants.

Region Analysis

North America dominates the global Liquid Biopsy Market, supported by strong adoption of precision diagnostics, high healthcare expenditure, and rapid commercialization of advanced genomic platforms. The United States remains a key contributor due to robust regulatory approvals, extensive clinical research, and widespread integration of liquid biopsy in cancer screening and treatment decision pathways.

Europe represents the second-largest regional market with increasing uptake of non-invasive testing, strong presence of biotechnology companies, and rising government focus on early cancer detection. Expanding reimbursement frameworks and investments in genomic screening programs further support market growth.

Asia Pacific is witnessing the fastest expansion, driven by improving healthcare infrastructure, rising awareness of early cancer diagnosis, and growing partnerships between global diagnostic companies and regional healthcare systems. Countries such as China, India, Japan, and South Korea are experiencing rapid adoption of NGS-based testing and high-throughput liquid biopsy technologies.

Latin America and the Middle East & Africa are steadily progressing with increasing investments in oncology diagnostics and expanding access to advanced testing tools. Strengthening research collaborations and the emergence of local diagnostic service providers are contributing to market development across these regions.

Key Players
• Guardant Health, Inc.
• Grail (Illumina, Inc.)
• ANGLE plc
• Hoffmann-La Roche Ltd.
• Invitae Corporation
• Myriad Genetics, Inc.
• Qiagen N.V.
• Exact Sciences Corporation
• MDxHealth SA
• Sysmex Inostics
• Biocept, Inc.
• NeoGenomics, Inc.
• Exosome Diagnostics, Inc.
• Personal Genome Diagnostics, Inc.
• Menarini-Silicon Biosystems
• Agena Bioscience, Inc.
• MedGenome Inc.
• Epigenomics AG
• Natera, Inc.
• Vortex Biosciences, Inc.

Global Liquid Biopsy Market Segmentation

By Biomarker
• Circulating Tumour Cells
• Circulating Tumour DNA
• Circulating free DNA
• Circulating Cell free RNA
• Exomes
• Other

By Source
• Blood
• Urine
• Other

By Clinical Application
• Diagnosis & Screening
• Treatment Selection
• Treatment Monitoring
• Recurrence Monitoring

By Indication
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Other Cancers
• Non-Oncology

By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Please note: Delivery Timelines - 5 working days. Show more